Research Topics
| J D AmsterdamSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution studyJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Am J Psychiatry 167:792-800. 2010..The authors hypothesized that fluoxetine monotherapy would be superior to lithium monotherapy with a similar hypomanic mood conversion rate...
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic inductionJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
J Affect Disord 87:121-30. 2005..This preliminary, placebo-controlled study examines the relative rates of treatment-emergent manic symptoms during fluoxetine monotherapy, olanzapine monotherapy, and combined fluoxetine plus olanzapine therapy of BP I and BP II MDE...
Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation studyJay D Amsterdam
Depression Research Unit, Department of Psychiatry bCenter for Clinical Epidemiology and Bio statistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Int Clin Psychopharmacol 20:257-64. 2005..Larger-scale studies are needed to confirm these findings...
MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective studyJay D Amsterdam
Depression Research Unit, University Science Center 3rd Floor, 3535 Market Street, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
J Affect Disord 89:183-8. 2005....
Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trialJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 26:579-86. 2006..In conclusion, STS was well tolerated and efficacious in maintaining a sustained response in MDD patients. The results of this study suggest that STS may be suitable in the long-term treatment of MDD...
Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitusJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
Neuropsychobiology 54:208-14. 2006..We examined the safety and efficacy of s-citalopram therapy in patients with co-morbid depression and diabetes, and its ability to improve glycemic control...
Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorderJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
Prog Neuropsychopharmacol Biol Psychiatry 32:100-6. 2008..Treatment of CFS has generally been disappointing. We hypothesized that s-citalopram therapy may improve the symptoms of both disorders in CFS patients with co-morbid depression...
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episodeJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Clin Psychopharmacol 30:306-11. 2010..We hypothesized that there would be a statistically significant reduction in depressive symptoms without a clinically meaningful increase in mood conversion symptoms...
Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label studyJay D Amsterdam
Department of Psychiatry, Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
J Clin Psychopharmacol 28:171-81. 2008..We hypothesized that initial AD monotherapy would be superior to MS monotherapy for BP II MDE with a low hypomanic switch rate...
Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trialJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
J Affect Disord 112:219-30. 2009..We hypothesized that lithium would have superior efficacy to venlafaxine, with fewer syndromal and sub-syndromal hypomanic and mixed mood conversions in the rapid cycling BP II MDE patients...
Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?Jay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
J Affect Disord 115:234-40. 2009..We hypothesized that a greater number of prior antidepressant exposures would result in a reduced response to venlafaxine, but not lithium, therapy...
Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorderJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
Neuropsychobiology 59:227-33. 2009..The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy...
A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorderJay D Amsterdam
Depression Research Unit, University Science Center, 3rd Floor, 3535 Market St, Philadelphia, PA 19104 3309, USA
J Clin Psychopharmacol 29:378-82. 2009..We hypothesized that chamomile would be superior to placebo in reducing GAD symptoms with a comparable tolerability profile...
Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapyJ D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Acta Psychiatr Scand 121:201-8. 2010..We hypothesized that venlafaxine would be superior to lithium with a low hypomanic conversion rate...
Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopauseJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
J Clin Psychopharmacol 29:478-83. 2009..We hypothesized that black cohosh would be superior to placebo in reducing anxiety symptoms of menopause, with a comparable tolerability profile to placebo...
A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controlsJay D Amsterdam
Department of Psychiatry, The Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Neuropsychobiology 55:167-70. 2007..We hypothesized that DAT levels might be higher in bipolar versus unipolar patients...
Antidepressant monotherapy for bipolar type II major depressionJay D Amsterdam
Department of Psychiatry, Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Bipolar Disord 5:388-95. 2003..Recent studies have provided evidence that antidepressant monotherapy may be an effective initial and long-term treatment for BP II major depression with a low manic-switch rate...
Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imagingDavid J Brunswick
Depression Research Unit, Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Am J Psychiatry 160:1836-41. 2003..The present study was an examination of the availability of brain dopamine transporter sites in patients with major depression and in healthy comparison subjects...
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorderJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
J Clin Psychiatry 64:208-14. 2003..This novel transdermal system provides targeted MAO inhibition without clinically significant increases in sensitivity to dietary tyramine. We investigated the safety and efficacy of STS in patients with major depressive disorder...
Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rateJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Bipolar Disord 6:75-81. 2004..This recommendation is the result of concern over antidepressant-induced manic switch episodes. However, recent evidence suggests that the manic switch rate may be low in BP II MDE during SSRI therapy...
A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--a putative, new antidepressantJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:1333-8. 2002..YKP10A is a novel, new antidepressant that may affect dopamine neurotransmission. We present results from the first Phase II clinical trial of YKP10A antidepressant activity in patients with major depression...
Site variability in treatment outcome in antidepressant trialsJay D Amsterdam
Depression Research Unit, Department of Psychiatry, 3rd Floor, University Science Center, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:989-93. 2002..As part of a five-site, long-term, double-blind, placebo-controlled, relapse prevention trial with fluoxetine in major depression, the authors examined site-specific variability in outcome ratings...
Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trialJay D Amsterdam
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, University Science Center, 3535 Market Street, 3rd Floor, Philadelphia, PA 19104, USA
J Psychiatr Res 38:259-65. 2004..Gepirone-IR was significantly more effective than placebo for relapse prevention and demonstrated acceptable tolerability in outpatient responders with MDD...
Prevention of relapse following cognitive therapy vs medications in moderate to severe depressionSteven D Hollon
Department of Psychology, Vanderbilt University, 306 Wilson Hall Nashville, TN 37203, USA
Arch Gen Psychiatry 62:417-22. 2005..Antidepressant medication prevents the return of depressive symptoms, but only as long as treatment is continued...
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depressionP J McGrath
Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, USA
J Clin Psychiatry 61:518-24. 2000..The goal was to examine predictors of relapse during continuation/maintenance treatment of major depression that had remitted following 12 to 14 weeks of fluoxetine therapy...
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapySunil S Bhar
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
J Affect Disord 110:161-6. 2008..The authors examined the patterns of improvement in cognitive and vegetative symptoms of major depression in individuals treated with cognitive therapy (CT) or pharmacotherapy (PT)...
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot studyDavid L Dunner
Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
J Clin Psychiatry 68:1071-7. 2007..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...
The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerabilityDonald S Robinson
Worldwide Drug Development, 102 East Avenue, Burlington, VT 05401, United States
J Affect Disord 105:15-23. 2008..Monoamine oxidase inhibitors (MAOIs) are highly efficacious antidepressants, but safety concerns have limited their broad use...
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyDavid Michelson
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
J Clin Psychiatry 68:582-7. 2007..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scaleAnita H Clayton
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, VA 22908, USA
J Clin Psychiatry 68:1860-6. 2007..The objective of this study was to examine the impact of STS 6 mg/24 hours on various domains of sexual function in patients with major depressive disorder (MDD), using a patient-rated questionnaire...
Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatientsJ Alexander Bodkin
McLean Hospital, 115 Mill St. Belmont, MA 02478, USA
Am J Psychiatry 159:1869-75. 2002..The typical side effects commonly seen with traditional monoamine oxidase inhibitor antidepressants were not observed...
Antidepressant drug effects and depression severity: a patient-level meta-analysisJay C Fournier
Department of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA
JAMA 303:47-53. 2010....
Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depressionJay C Fournier
Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
J Consult Clin Psychol 77:775-87. 2009..The 3 prognostic variables identify subgroups that might benefit from alternative treatment strategies; the 3 prescriptive variables identify groups who appear to respond particularly well to cognitive therapy...
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatmentDavid J Brunswick
The Depression Research Unit, University of Pennsylvania Medical Center, University Science Center, 8th Floor, 3600 Market Street, Philadelphia, PA 19104, USA
J Affect Disord 68:243-9. 2002..The purpose of this study was to investigate the relationship between steady-state plasma drug concentrations and outcome during relapse-prevention therapy with fluoxetine...
The relation of patients' treatment preferences to outcome in a randomized clinical trialYan Leykin
Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
Behav Ther 38:209-17. 2007..These results do not provide support for the claim that the external validity of randomized controlled trials suffers from this aspect of the randomization procedure...
PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depressionMartin Reivich
Cerebrovascular Research Center, Department of Neurology, University of Pennsylvania School of Medicine, Room 415 Stemmler Hall, Philadelphia, PA 19104 6063, USA
J Affect Disord 82:321-7. 2004....
Cognitive therapy vs medications in the treatment of moderate to severe depressionRobert J Derubeis
Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
Arch Gen Psychiatry 62:409-16. 2005..There is substantial evidence that antidepressant medications treat moderate to severe depression effectively, but there is less data on cognitive therapy's effects in this population...
Mood disorders in women from adolescence to late life: an overviewRhonda C Boyd
Department of Psychiatry, University of Pennsylvania School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
Clin Obstet Gynecol 47:515-26. 2004
123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary studyAndrew B Newberg
Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
J Nucl Med 46:973-7. 2005..We hypothesized that SERT binding activity may be altered in patients with MDD. This study compared SERT binding in patients with MDD with that in healthy controls...
A prospective trial of sertraline for chronic subjective dizzinessJeffrey P Staab
Department of Psychiatry, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
Laryngoscope 114:1637-41. 2004....
Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depressionYan Leykin
Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
J Consult Clin Psychol 75:267-76. 2007..If these findings are replicated in methodologically rigorous studies of paroxetine and other antidepressants, CT should be recommended, in preference to AD, for patients with multiple prior AD exposures...
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implicationsCristina Cusin
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 68:52-7. 2007..While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated...
Antidepressant medications v. cognitive therapy in people with depression with or without personality disorderJay C Fournier
Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
Br J Psychiatry 192:124-9. 2008..There is conflicting evidence about comorbid personality pathology in depression treatments...
Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depressionMady Hornig-Rohan
Depression Research Unit, University Science Center, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:585-9. 2002..Controlled, prospective trials with larger patient samples will be needed to confirm these preliminary observations...
The effect of post-injury depression on return to pre-injury function: a prospective cohort studyT S Richmond
University of Pennsylvania, Philadelphia, 19104, USA
Psychol Med 39:1709-20. 2009..Little is known about the effect of psychiatric co-morbid disorders that emerge after minor injury on functional recovery. This study examined the effect of post-injury depression on return to pre-injury levels of function...
Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjectsDavid J Brunswick
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Prog Neuropsychopharmacol Biol Psychiatry 28:477-80. 2004..CONCLUSIONS: These results suggest that SSRI augmentation with usual clinical doses of pindolol does not increase central synaptic 5-HT neurotransmission sufficient to induce an enhanced neuroendocrine response...
Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depressionM P Szuba
University of Pennsylvania, Department of Psychiatry, Philadelphia, Pennsylvania 19104, USA
Biol Psychiatry 50:22-7. 2001..CONCLUSIONS: This blinded, placebo-controlled trial documents that individual rTMS sessions can acutely elevate mood and stimulate TSH release in patients experiencing major depressive episodes...
Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depressionMartin P Szuba
Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, University Science Center, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 25:325-30. 2005..CONCLUSIONS: Nocturnal TRH administration may produce a rapid antidepressant effect in some patients with BP I and BP II MDE...
Neuroendocrine aspects of chronic fatigue syndromeDimitris A Papanicolaou
Department of Medicine/Endocrinology, Emory University, Atlanta, GA, USA
Neuroimmunomodulation 11:65-74. 2004..This paper represents the consensus of the panel of experts who participated in this meeting...
Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of HealthTimothy R Gerrity
Worcester Polytechnic Institute, Worcester, Mass, USA
Neuroimmunomodulation 11:351-7. 2004..It has become clear that CFS cannot be understood based on single measurements of immune, endocrine, cardiovascular, or autonomic nervous system dysfunction. This panel encourages a new emphasis on multidisciplinary research into CFS...
Research Grants
- 1/2-Prevention of Relapse & Recurrence of Bipolar DepressionJay D Amsterdam; Fiscal Year: 2010..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
- Treatment of Bipolar Type II Major DepressionJay D Amsterdam; Fiscal Year: 2010..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
- Long-Term Chamomile Therapy of Generalized Anxiety DisorderJay Amsterdam; Fiscal Year: 2009..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..
- 1/2-Prevention of Relapse & Recurrence of Bipolar DepressionJay Amsterdam; Fiscal Year: 2009..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
- Treatment of Bipolar Type II Major DepressionJay Amsterdam; Fiscal Year: 2007..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
- SPECT Brain Imaging as a Biomarker of Major DepressionJay Amsterdam; Fiscal Year: 2007..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
- Chamomile therapy for generalized anxiety disorderJay Amsterdam; Fiscal Year: 2006....
- Black cohosh therapy for menopause-related anxietyJay Amsterdam; Fiscal Year: 2006..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
- RELAPSE PREVENTION OF BIPOLAR TYPE-II DISORDERJay Amsterdam; Fiscal Year: 2005..We believe that our study has the potential to have a significant impact upon current clinical practice in the appropriate management of bipolar depressed patients; an extremely important public-health matter. ..
- Long-Term Chamomile Therapy of Generalized Anxiety DisorderJay D Amsterdam; Fiscal Year: 2010..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..
